ProfileGDS5678 / 1415834_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 96% 96% 95% 95% 96% 96% 95% 95% 95% 96% 96% 95% 96% 96% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 18.8137796
GSM967853U87-EV human glioblastoma xenograft - Control 28.8851896
GSM967854U87-EV human glioblastoma xenograft - Control 38.6348295
GSM967855U87-EV human glioblastoma xenograft - Control 48.4979495
GSM967856U87-EV human glioblastoma xenograft - Control 58.8044996
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 18.5638196
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 28.1556495
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 38.5957895
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 48.4834295
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 18.7472996
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 28.9177596
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 38.6512295
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 48.8148496
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 58.7485696